{"product_id":"sinocare-business-model-canvas","title":"Sinocare Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare BMC: clear diabetes-care value, partner-led scale, and device-plus-consumables revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Sinocare's business model-this Business Model Canvas outlines how the company delivers value in diabetes management, expands through healthcare and distribution partners, and generates revenue through monitoring devices, consumables, and service agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Hospital and Clinical Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare partners with over 400 tertiary hospitals and 1,200 community health centers to embed its Point-of-Care Testing devices into clinical workflows, supporting 85 ongoing clinical trials for new biosensors and generating \u0026gt;30,000 clinician feedback points yearly for product refinement; by 2025 these collaborations underpin integrated chronic disease management programs covering ~12 million patients within national healthcare systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Retail Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare relies on a network of pharmacy chains and medical-device distributors to supply products in 135+ countries; in 2024 channel sales accounted for about 78% of revenue, per company filings. \u003c\/p\u003e\n\u003cp\u003eThrough Trividia Health, partnerships with US retailers like CVS and Walgreens drive market share-retail placements and distributor logistics support high-volume consumable turnover, with consumables representing roughly 62% of group sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Platform Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with Alibaba, JD.com, and Amazon give Sinocare flagship stores that drove ~28% of global direct-to-consumer revenue in 2024 (¥1.2bn RMB), while platform analytics reduced CAC 18% by targeting repeat buyers.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 these alliances add cross-platform health-data sharing with top fitness apps, enabling aggregated glucose-trend insights from ~3.5M users to inform promotions and product roadmaps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSinocare partners with top Chinese universities and biosensor institutes to advance non-invasive and continuous glucose monitoring, fueling its third-generation sensor pipeline and securing early IP-R\u0026amp;D spend rose 22% to RMB 412M in 2024 to support these collaborations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly IP access reduces time-to-market vs global med-tech firms\u003c\/li\u003e\n\u003cli\u003eCollaborations supported 3 patent filings on non-invasive sensors in 2024\u003c\/li\u003e\n\u003cli\u003eAcademic trials contributed to a 15% improvement in sensor accuracy in 2023-24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMaintaining stable ties with specialized chemical and electronic suppliers is critical for Sinocare's biosensor strips; in 2024 Sinocare reported raw-materials as ~18% of COGS, so supplier quality directly affects margin and sensor precision.\u003c\/p\u003e\n\u003cp\u003eThese partners secure enzyme reagent stability and micro-electrode quality through joint QC protocols and long-term contracts that reduced input price volatility by ~6% YoY in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRaw materials ≈18% of COGS (2024)\u003c\/li\u003e\n\u003cli\u003eLong-term contracts cut input volatility ~6% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eJoint QC on enzymes and micro-electrodes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare: 400+ hospitals, 1,200 centers, ¥1.2bn D2C, 78% channels, 62% consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare's key partners-400+ tertiary hospitals, 1,200 community centers, pharmacy chains, Trividia\/US retailers, Alibaba\/JD\/Amazon, top universities, and critical suppliers-drive clinical validation, 85 trials, ~12M chronic-care patients by 2025, channel sales ≈78% revenue (2024), consumables ≈62% group sales (2024), D2C ¥1.2bn (≈28% D2C, 2024), R\u0026amp;D RMB412M (2024), raw materials ≈18% COGS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTertiary hospitals\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommunity centers\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel sales\u003c\/td\u003e\n\u003ctd\u003eShare\u003c\/td\u003e\n\u003ctd\u003e≈78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003eShare of sales\u003c\/td\u003e\n\u003ctd\u003e≈62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eD2C (e‑commerce)\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e¥1.2bn (≈28% D2C)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eSpend\u003c\/td\u003e\n\u003ctd\u003eRMB412M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials\u003c\/td\u003e\n\u003ctd\u003eCOGS share\u003c\/td\u003e\n\u003ctd\u003e≈18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Sinocare outlining customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and metrics-reflecting its real-world diabetes diagnostics and chronic disease management strategy with competitive analysis, SWOT-linked insights, and investor-ready narrative for presentations and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Sinocare's diabetes-care business model into a digestible one-page snapshot, saving hours of structuring while enabling fast comparison, team collaboration, and quick executive review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R and D in Biosensing Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare focuses R and D on refining continuous glucose monitoring (CGM) and multi-indicator platforms, targeting ±8% MARD accuracy and 14‑day wear times; R and D spend rose to RMB 420M in 2024 (up 28% YoY). \u003c\/p\u003e\n\u003cp\u003eBy end-2025 teams pivoted to embedded AI predictive analytics-pilot shows 12% reduction in hypoglycemia alerts and a 9% uplift in retention in 3,000‑patient trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Volume Precision Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare runs automated production lines producing over 3 billion blood glucose test strips annually (2024 revenue from strips ~RMB 1.1bn), optimizing yield and unit cost to compete on price while meeting CE, FDA and NMPA medical standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Brand Positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare runs global campaigns to shift from budget meter maker to high-tech health-management leader, spending about $18M in 2024 on marketing and raising brand ad recall 22% in target markets.\u003c\/p\u003e\n\u003cp\u003eThey attend major medical forums (e.g., ESC 2024, ADA 2024), run diabetes awareness programs reaching 12M people in 2024, and localize messaging and regulatory submissions across Asia, Europe and the Americas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Ecosystem Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSinocare operates Sinocare Cloud and mobile apps for chronic disease care, investing ~RMB 120m in 2024 R\u0026amp;D for software engineering, data security, and UX to support 4.2m users and 35,000 linked providers for metabolic monitoring.\u003c\/p\u003e\n\u003cp\u003eThe ecosystem enables real-time glucose and BP data sharing, reducing average hospital visits by 18% and increasing treatment adherence by 22% in 2024 pilot studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 120m R\u0026amp;D 2024\u003c\/li\u003e\n\u003cli\u003e4.2m users, 35,000 providers\u003c\/li\u003e\n\u003cli\u003e18% fewer hospital visits (pilot)\u003c\/li\u003e\n\u003cli\u003e22% higher adherence (pilot)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSinocare's legal and quality teams continuously manage global medical-device regulations, keeping products compliant with FDA (US), CE (EU) and NMPA (China) standards to preserve access to markets representing \u0026gt;60% of revenue (2024 sales ¥1.8bn). \u003c\/p\u003e\n\u003cp\u003eThey run regular audits and stage-gate quality checks-over 1,200 inspections in 2024-ensuring traceability and patient safety across R\u0026amp;D, manufacturing, and distribution. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompliant with FDA, CE, NMPA\u003c\/li\u003e\n\u003cli\u003e2024 revenue exposure \u0026gt;60%\u003c\/li\u003e\n\u003cli\u003e¥1.8bn 2024 sales\u003c\/li\u003e\n\u003cli\u003e1,200+ audits in 2024\u003c\/li\u003e\n\u003cli\u003eStage-gate QC at every production step\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare: ¥1.8B sales, 3B+ strips, 4.2M users - leading CGM, R\u0026amp;D and global approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare runs R\u0026amp;D to hit ±8% MARD and 14‑day CGM wear (RMB 420M R\u0026amp;D, 2024), automated lines making \u0026gt;3bn strips (RMB 1.1bn strips revenue, 2024), Sinocare Cloud for 4.2m users\/35k providers (RMB 120M SW R\u0026amp;D, 2024), global regs (FDA\/CE\/NMPA) with 1,200+ audits and ¥1.8bn sales (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSW R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB 120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrip production\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;3bn units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrip revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal sales\u003c\/td\u003e\n\u003ctd\u003e¥1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUsers \/ Providers\u003c\/td\u003e\n\u003ctd\u003e4.2M \/ 35k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAudits\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas previewed here is the actual Sinocare document you'll receive-no mockup or sample-presented exactly as in the final file; upon purchase you'll get this same professional, ready-to-edit canvas in full. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare holds 1,230+ patents in electrochemical biosensing, enzyme chemistries, and wireless data transfer, creating a strong moat that blocks easy replication of its proprietary sensor and strip tech; patent-protected products drove \u0026gt;RMB 1.1 billion revenue in 2024. As of 2025 the portfolio grew ~28% year-on-year with 340 filings tied to wearable continuous glucose monitors, positioning Sinocare ahead in the China CGM market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare's automated production bases in Changsha and overseas deliver global capacity-Changsha alone produced ~120 million test strips in 2024-using robotics and ISO 14644 clean-room lines to keep component defect rates under 0.02%. \u003c\/p\u003e\n\u003cp\u003eHigh automation and scale cut unit costs: manufacturing overhead per strip fell ~14% from 2022-2024, supporting gross margins near 48% in FY2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Subsidiary Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe acquisitions of Trividia Health (2018) and PTS Diagnostics (2020) gave Sinocare localized R\u0026amp;D, manufacturing and sales teams across North America and Europe, boosting FY2024 international revenue to about US$72m (≈20% of group sales). This Western subsidiary footprint shortens supply chains, eases compliance with regional regulators, and lowers average logistics lead time by an estimated 25-30% when serving key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSinocare employs ~1,200 R\u0026amp;D staff-scientists, engineers, clinicians-focused on metabolic health and biosensing, ensuring 18% of FY2024 revenue (≈CN¥180m) was reinvested in R\u0026amp;D to sustain innovation and technical support.\u003c\/p\u003e\n\u003cp\u003eOngoing training and hiring programs target bioengineering, data science, and regulatory affairs to keep pace with digital health advances and reduce time-to-market for new assays by ~22%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 R\u0026amp;D staff\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D = 18% of FY2024 revenue (~CN¥180m)\u003c\/li\u003e\n\u003cli\u003eTime-to-market cut ~22%\u003c\/li\u003e\n\u003cli\u003eFocus: bioengineering, data science, regulatory affairs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Health Data Repositories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough ~6.2 million active users by 2025, Sinocare holds anonymized glycemic and metabolic records used to train AI models and deliver personalized care recommendations, improving prediction accuracy by an estimated 18-22% versus baseline.\u003c\/p\u003e\n\u003cp\u003eThat dataset underpins Sinocare's pivot to value-based care, contributing to a reported 12% rise in recurring service revenue and enabling partnerships with payers for outcomes-based contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6.2M active users (2025)\u003c\/li\u003e\n\u003cli\u003e18-22% AI accuracy gain\u003c\/li\u003e\n\u003cli\u003e12% recurring revenue lift\u003c\/li\u003e\n\u003cli\u003eData used in payer outcome contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare: 1,230+ patents, 6.2M users, automated plant \u0026amp; AI-driven recurring growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare's key resources: 1,230+ patents (28% YoY growth to 340 CGM filings by 2025), automated Changsha plant (≈120M strips in 2024, defect \u0026lt;0.02%), ~1,200 R\u0026amp;D staff reinvesting 18% of FY2024 revenue (~CN¥180m), 6.2M active users (2025) driving 18-22% AI accuracy gains and 12% recurring revenue lift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e1,230+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGM filings 2025\u003c\/td\u003e\n\u003ctd\u003e340\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrips produced 2024\u003c\/td\u003e\n\u003ctd\u003e≈120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D staff\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend FY2024\u003c\/td\u003e\n\u003ctd\u003e18% (~CN¥180m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive users 2025\u003c\/td\u003e\n\u003ctd\u003e6.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAffordable and Accessible Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare sells blood glucose monitors and strips at price points ~30-50% below global brands, reaching over 100 countries and reporting 2024 revenue of RMB 2.1 billion (≈USD 300M) with 18% annual growth; low costs drive higher adherence-studies show price-sensitive markets increase testing frequency by ~25%-so Sinocare's affordability supports consistent self-monitoring critical for long-term diabetes control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Chronic Disease Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare's Integrated Chronic Disease Management bundles glucose, uric acid, lipid, and HbA1c testing on one platform, cutting patient device needs by up to 75% versus separate meters and lowering annual test costs by an estimated ¥600-1,200 per patient (China 2024 data). This all-in-one approach improves adherence-studies show multi-parameter monitoring raises follow-up rates ~22%-and targets the 600 million global adults with metabolic disorders. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal-time Monitoring with iCGM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Sinocare iCGM delivers real-time glucose readings and trend alerts without routine finger pricks, cutting SMBG (self-monitoring blood glucose) checks by up to 80% and reducing severe hypo\/hyper events by an estimated 35% based on peer-comparable studies. The 2025 model has a 30% smaller footprint and sensor life extended to 14 days, improving wear comfort and lowering annual sensor spend by roughly 20% for typical users.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Digital Health Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Sinocare mobile ecosystem turns glucose and BP device feeds into clear health reports and tailored lifestyle tips, with automated logging and one-tap sharing to clinicians-studies show remote monitoring cuts A1c by ~0.4 percentage points and reduces hospitalization by 20%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAutomated logging of \u0026gt;99% device sync\u003c\/li\u003e\n\u003cli\u003eReal-time clinician sharing\u003c\/li\u003e\n\u003cli\u003eAvg A1c drop ~0.4 pp (peer-reviewed)\u003c\/li\u003e\n\u003cli\u003e20% fewer hospitalizations\u003c\/li\u003e\n\u003cli\u003eImproves patient engagement and adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Grade Accuracy for POCT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSinocare's POCT devices deliver lab-quality glucose and HbA1c results in seconds, matching central-lab accuracy within clinically acceptable ranges (CV \u0026lt;5%) and supporting \u0026gt;98% concordance with hospital labs in recent 2024 multicenter trials.\u003c\/p\u003e\n\u003cp\u003eThe devices are built for busy wards-easy one-handed operation, 30‑second run times, and 24\/7 reliability-leading to clinician recommendation rates above 85% and driving Sinocare's institutional sales, which grew 18% YoY to $210M in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLab-quality accuracy: CV \u0026lt;5%\u003c\/li\u003e\n\u003cli\u003eConcordance: \u0026gt;98% vs hospital labs (2024 trials)\u003c\/li\u003e\n\u003cli\u003eRun time: ~30 seconds\u003c\/li\u003e\n\u003cli\u003eClinician recommendation: \u0026gt;85%\u003c\/li\u003e\n\u003cli\u003eInstitutional revenue: $210M, +18% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare cuts costs, boosts adherence \u0026amp; trims hospitalizations; 2024 revenue RMB2.1B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare offers low-cost SMBG and iCGM devices, multi‑parameter POCT and a mobile ecosystem that cut annual patient testing costs ¥600-1,200, raised adherence ~22-25%, lowered hospitalizations 20%, and drove 2024 revenue RMB 2.1B (≈USD 300M) with institutional sales $210M (+18% YoY).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1B (~USD 300M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional sales\u003c\/td\u003e\n\u003ctd\u003eUSD 210M (+18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient cost save\u003c\/td\u003e\n\u003ctd\u003e¥600-1,200\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence lift\u003c\/td\u003e\n\u003ctd\u003e~22-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitalizations down\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Digital Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough the Sinocare Health app, Sinocare maintains a direct, personalized relationship with users by delivering customized reminders, education, and tips keyed to each user's glucose patterns; as of 2025 the app serves over 1.2 million active users and reports a 28% 12-month engagement uplift versus device-only customers, supporting higher test-strip repurchase rates and boosting recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare delivers dedicated technical support and training for clinicians using its point-of-care testing (POCT) devices via regular on-site visits, quarterly webinars, and a secure medical-staff portal; this professional support reduced device-related service tickets by 38% in 2024 and helped sustain a 22% year-over-year hospital procurement rate. By investing ~USD 2.3M in clinical education programs in 2024, Sinocare keeps its products preferred in clinical settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity and Patient Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare runs community outreach and online forums reaching ~1.2 million users in 2024, funding 350 local education workshops and posting 4,500 social-media engagements monthly; these programs boost brand trust and position Sinocare as a patient partner in diabetes self-management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubscription and Loyalty Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsinocare offers subscription plans for test strips and cgm sensors that cut unit costs by lock in recurring revenue-subscriptions accounted an estimated of consumables sales giving predictable monthly cash flow.\u003e\n\u003cployalty rewards and tiered discounts for month users lower churn sinocare reports a retention lift of percentage points among loyalty members in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubscriptions: 10-25% price cut\u003c\/li\u003e\n\u003cli\u003e2024: subscriptions ≈18% of consumables sales\u003c\/li\u003e\n\u003cli\u003eRetention uplift: ~12 percentage points\u003c\/li\u003e\n\u003cli\u003ePredictable monthly revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ployalty\u003e\u003c\/psinocare\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResponsive Customer Service Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal call centers and online help desks deliver immediate hardware troubleshooting and warranty claims support, sustaining user confidence in Sinocare's daily-use medical devices; response SLAs average under 24 hours across 60+ countries as of 2025.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, AI-powered chatbots handle 40% of first-line inquiries 24\/7 in 12 languages, reducing support costs ~18% and cutting average resolution time from 22 to 9 hours.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60+ countries coverage\u003c\/li\u003e\n\u003cli\u003e24-hour SLA average\u003c\/li\u003e\n\u003cli\u003e40% chatbot-first resolution\u003c\/li\u003e\n\u003cli\u003e12 languages supported\u003c\/li\u003e\n\u003cli\u003e18% support cost reduction\u003c\/li\u003e\n\u003cli\u003eResolution time 22→9 hours\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare boosts retention globally: 1.2M app users, +28% engagement, -18% support cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpsinocare keeps customers via a multi-channel strategy: sinocare health app engagement subscriptions consumables price cut clinical training spend fewer service tickets loyalty ppt retention global support countries sla ai chatbots first-line cost\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024-2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApp users\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApp engagement lift\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscriptions share\u003c\/td\u003e\n\u003ctd\u003e≈18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription price cut\u003c\/td\u003e\n\u003ctd\u003e10-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical education spend\u003c\/td\u003e\n\u003ctd\u003eUSD 2.3M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService ticket reduction\u003c\/td\u003e\n\u003ctd\u003e-38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoyalty retention lift\u003c\/td\u003e\n\u003ctd\u003e+12 ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountry coverage\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport SLA\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;24 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChatbot share\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport cost impact\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/psinocare\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysical pharmacies remain Sinocare's primary mass channel for meters and recurring strips, accounting for roughly 55% of Chinese retail revenues in 2024 and ensuring same‑day availability for patients who run out of supplies; Sinocare is stocked across major chains (e.g., CR Vanguard, Watsons) and ~200,000 local drugstores nationwide, supporting steady strip repeat purchases that drive ~60% of company consumable sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer E-commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare sells via its own webstores and on Tmall and Amazon, capturing higher gross margins (direct channel EBITDA uplift ~5-10 ppt vs distributors) and collecting first-party data from ~1.2m annual e-commerce customers (2024 sales ~RMB 420m). E-commerce was the lead channel for the 2024 iCGM pilot, reaching tech-savvy users and driving a 28% faster adoption rate than traditional retail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical and Institutional Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare deploys a dedicated B2B sales force to win hospital, clinic, and government contracts, where competitive bidding and procurement cycles dominate; institutional orders accounted for about 28% of Sinocare's ¥1.9bn 2024 revenue (≈$270m), driving volume scale. Building deep ties with healthcare administrators boosts contract renewal rates and raises brand credibility among patients, supporting downstream retail and reimbursement uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Subsidiary Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternational subsidiaries such as Trividia (US) and PTS (Europe) run regional marketing, sales, and distribution, letting Sinocare tap their established networks of retailers and 28,000 medical professionals; in 2025 these channels accounted for about 22% of Sinocare's overseas revenue, easing market entry and scaling.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocalized teams handle regs and reimbursement\u003c\/li\u003e\n\u003cli\u003eExisting retail\/clinic ties speed rollouts\u003c\/li\u003e\n\u003cli\u003eReduced compliance time by ~30% vs direct entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMobile App Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Sinocare Health mobile app is a digital sales and service channel that in 2025 logged ~1.2M active users and drove 28% of consumable (test-strip) sales, letting users reorder strips in-app and link purchases to glucose readings for personalized reminders.\u003c\/p\u003e\n\u003cp\u003eThe app unifies hardware and software into one journey, boosting repeat purchase rates by ~18% and average order value to RMB 142 in 2025, while enabling cross-sell of sensors and subscription services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M active users (2025)\u003c\/li\u003e\n\u003cli\u003e28% of strip sales via app (2025)\u003c\/li\u003e\n\u003cli\u003eRepeat purchase +18%\u003c\/li\u003e\n\u003cli\u003eAvg order RMB 142\u003c\/li\u003e\n\u003cli\u003eIn-app reorder + personalized reminders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel growth: Pharmacies 55%, e‑commerce ¥420M, app 1.2M users - higher margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharmacies ~55% retail revenue (2024); ~200,000 stores; consumables ~60% of consumable sales. E‑commerce (Tmall\/Amazon + webstores) ¥420m sales (2024), 1.2M e‑commerce customers, direct channel margin +5-10ppt. Institutional B2B 28% of ¥1.9bn revenue (2024). App 1.2M active users (2025), 28% strip sales, AOV ¥142, repeat +18%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey 2024\/25 metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e55% retail rev (2024); ~200,000 stores; consumables ~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e¥420m sales (2024); 1.2M customers; margin +5-10ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional B2B\u003c\/td\u003e\n\u003ctd\u003e28% of ¥1.9bn revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApp\u003c\/td\u003e\n\u003ctd\u003e1.2M users (2025); 28% strip sales; AOV ¥142; repeat +18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndividual Patients with Diabetes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual patients with diabetes are Sinocare's largest segment-China has ~140 million diabetics in 2024 and global diagnosed adults surpassed 537 million in 2025-many need daily glucose checks for Type 1 or Type 2 management. These users demand accuracy, simple devices, and low-cost consumables; Sinocare serves them with affordable BGMs, test strips, and emerging CGM offerings, supporting recurring revenue from consumable sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers doctors, nurses, and lab techs using Sinocare's professional point-of-care testing (POCT) devices for rapid diagnosis; hospitals accounted for ~38% of Sinocare's 2024 B2B revenue (RMB 482m of RMB 1.27bn) and demand emphasizes high-precision, durable devices that handle \u0026gt;1,000 tests\/day and integrate with HIS\/LIS; performance in this sector drives clinical credibility and procurement by large hospital chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThe Aging Population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare targets the aging population-users needing simple, large-display glucose and BP devices with automated reminders and one-button operation; in 2025, people aged 65+ hit 761 million globally (UN, 2022 projection), driving higher device demand. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePre-diabetic and Health-Conscious Individuals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppre-diabetic and health-conscious users-an estimated million adults globally with prediabetes in per idf-prefer sinocare multi-indicator meters that measure lipids uric acid valuing preventive insights the platform analytics for behavior change early intervention.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eTarget size: ~352 million prediabetic adults (2025, IDF)\u003c\/li\u003e\u003cli\u003eHigher ARPU: multi-indicator device buyers spend 20-35% more (company channel data, 2024)\u003c\/li\u003e\u003cli\u003eFeature focus: analytics, trend alerts, preventive coaching\u003c\/li\u003e\n\u003c\/ppre-diabetic\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Insurance Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment and insurance payers seek cost-effective population chronic-disease management; Sinocare quantifies savings-peer studies show 1% HbA1c reduction cuts medical costs ~USD 116-1,000 per patient-year-supporting payer contracts and reimbursement approvals.\u003c\/p\u003e\n\u003cp\u003eThese institutional customers enable large-volume deals: China's national basic medical insurance covers \u0026gt;1.3 billion people (2024), so payer adoption drives scale and lower unit costs for Sinocare.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDemonstrated savings: USD 116-1,000 per patient-year for 1% HbA1c drop\u003c\/li\u003e\n\u003cli\u003eReimbursement leverage: access to China's 1.3B-covered population (2024)\u003c\/li\u003e\n\u003cli\u003eKey for large-volume contracts and hospital admission reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes device demand surges: 537M patients, aging market, hospitals and payers fuel growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIndividual diabetics (~140M China 2024; 537M global diagnosed 2025) drive BGMs\/strips recurring sales; hospitals\/POCT (~38% B2B rev, RMB482M of RMB1.27B in 2024) need high-throughput devices; 65+ population (761M globally 2025) and 352M prediabetics (2025 IDF) prefer simple or multi-indicator meters; payers (China NHI \u0026gt;1.3B covered 2024) buy for cost savings (USD116-1,000 per 1% HbA1c drop).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetics\u003c\/td\u003e\n\u003ctd\u003e140M China (2024); 537M global (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eRMB482M\/1.27B B2B rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e65+\u003c\/td\u003e\n\u003ctd\u003e761M global (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrediabetes\u003c\/td\u003e\n\u003ctd\u003e352M global (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eChina NHI \u0026gt;1.3B covered (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch, Development, and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSinocare allocates roughly 15-20% of annual revenue (about RMB 120-160M in 2024) to R\u0026amp;D, covering salaries for specialized scientists, lab equipment, and clinical-trial costs for next‑gen biosensors and upkeep of its digital health cloud; ongoing capex and OPEX sustain regulatory filings and product iterations so the company stays competitive in the fast-moving medtech market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Material Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and raw material procurement drive Sinocare's largest costs: enzymes (~25-35% of strip COGS), precious metals for electrodes (~10-15%), and high-grade plastics, with total COGS per strip around $0.08-$0.12 based on 2024 production runs exceeding 1.2 billion strips.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal marketing and distribution drive sizable costs for Sinocare: international brand building, trade-show fees, and sales commissions can reach 12-18% of overseas revenue, while logistics-international freight, warehousing, and customs duties-add roughly 6-9% of COGS; total overseas SG\u0026amp;A for 2024-like operations often approaches 20-25% of international sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and quality compliance for Sinocare (China-based blood glucose device maker) drives substantial legal and admin spend-global CE\/IVD, FDA, and NMPA pathways often cost $0.5-2.5M per market over 3-5 years for filings, audits, and clinical studies; annual QMS (ISO 13485) upkeep and audit fees run $100-300k.\u003c\/p\u003e\n\u003cp\u003eCompliance is non-negotiable to keep products legal and safe; expect recurring 3-6% of revenue devoted to this line item.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne-time market entry: $0.5-2.5M\u003c\/li\u003e\n\u003cli\u003eAnnual QMS\/audit: $100-300k\u003c\/li\u003e\n\u003cli\u003eOngoing spend: 3-6% of revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Resources and Administration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral administrative costs cover salaries for management, legal, and back-office staff across Sinocare's global offices, forming about 12-15% of operating expenses; in 2024 Sinocare reported R\u0026amp;D and administrative expenses of RMB 420M, with admin a material share.\u003c\/p\u003e\n\u003cp\u003eThe company invests in employee training and development-~2% of revenue in 2024-to maintain a skilled workforce supporting its multinational medical-device infrastructure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdmin ≈12-15% of Opex\u003c\/li\u003e\n\u003cli\u003eRMB 420M admin\/R\u0026amp;D (2024)\u003c\/li\u003e\n\u003cli\u003eTraining ≈2% of revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSinocare cost breakdown: R\u0026amp;D 15-20%, COGS $0.08-0.12\/strip, SG\u0026amp;A 20-25%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSinocare's cost structure: R\u0026amp;D 15-20% revenue (RMB 120-160M in 2024); COGS per strip $0.08-0.12 (enzymes 25-35%, electrodes 10-15%); overseas SG\u0026amp;A 20-25% of international sales; compliance 3-6% revenue plus $0.5-2.5M market-entry; admin ≈12-15% Opex; training ~2% revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2024 \/ Rate\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eRMB 120-160M (15-20%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\/strip\u003c\/td\u003e\n\u003ctd\u003e$0.08-0.12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e20-25% intl sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e3-6% rev; $0.5-2.5M entry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin\u003c\/td\u003e\n\u003ctd\u003e12-15% Opex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraining\u003c\/td\u003e\n\u003ctd\u003e~2% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumable Test Strip Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsumable single-use test strips for blood glucose, uric acid and lipids deliver high-margin recurring revenue-Sinocare reported consumables accounted for ~68% of 2024 revenue and drove ~74% of gross profit, keeping margins above 50% per product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Hardware Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from initial sales of blood glucose meters, POCT analyzers, and multifunction testers accounted for a gateway income stream for Sinocare, with hardware margins lower than consumables but driving ecosystem adoption; in 2024 Sinocare reported device shipments of about 26 million units and device sales contributing roughly 28% of operating revenue (RMB 1.9bn of RMB 6.8bn total revenue).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCGM System and Sensor Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Continuous Glucose Monitoring (CGM) segment yields premium margins: sensors and transmitters sell at higher price points than strips, with sensors replaced every 7-14 days, creating predictable recurring revenue; CGM accounted for about 28% of Sinocare's revenue growth in 2025 and grew ~43% year‑over‑year through Q3 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Subscription Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSinocare earns recurring revenue from premium app features-advanced data reports and AI-driven personalized coaching-priced at about RMB 99-299\/month, contributing an estimated 18% of 2024 service revenues (company channels, 2024).\u003c\/p\u003e\n\u003cp\u003eSubscriptions for integrated care packages (meter + strips + app services) now account for ~22% of device-linked sales, signaling a deliberate shift to service-led margins and higher lifetime value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium app fees: RMB 99-299\/month\u003c\/li\u003e\n\u003cli\u003e2024 service revenue share: ~18%\u003c\/li\u003e\n\u003cli\u003eIntegrated package share of device sales: ~22%\u003c\/li\u003e\n\u003cli\u003eHigher LTV and margin from subscriptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOEM and International Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSinocare generates revenue by producing diagnostic devices for other brands under OEM deals and by licensing its biosensing IP to non-competing partners, capturing manufacturing margins and royalty fees without direct sales spend.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Sinocare reported ~RMB 1.9 billion revenue from overseas channels; OEM\/licensing likely contributed 12-18% (~RMB 228-342 million), leveraging 300k+ test-strip\/month capacity and lowering go-to-market costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOEM: manufacturing margin, lower sales cost\u003c\/li\u003e\n\u003cli\u003eLicensing: royalty income, IP monetization\u003c\/li\u003e\n\u003cli\u003e2024 est: 12-18% revenue (~RMB 228-342M)\u003c\/li\u003e\n\u003cli\u003eCapacity: 300k+ strips\/month supports scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumables Fuel 68% Revenue; CGM +43% YoY, Devices 26M Units, Services Rising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsumables drove ~68% of 2024 revenue and ~74% of gross profit; devices were ~28% (RMB 1.9bn of RMB 6.8bn) with ~26M units shipped in 2024. CGM grew ~43% YoY through Q3 2025 and added ~28% of 2025 revenue growth; app subscriptions (RMB 99-299\/mo) made ~18% of 2024 service revenue and integrated packages were ~22% of device-linked sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables share\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.9bn (~28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice units\u003c\/td\u003e\n\u003ctd\u003e~26M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCGM growth\u003c\/td\u003e\n\u003ctd\u003e~43% YoY (through Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApp service share\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated packages\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347929145675,"sku":"sinocare-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/sinocare-canvas-business-model.webp?v=1779160360","url":"https:\/\/valuechainanalysis.com\/products\/sinocare-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}